62/100

Fate Therapeutics

FATECell Therapy

📋

Analyst Summary

✓ VERIFIED2026-04-11

Fate Therapeutics (FATE) is the lead sponsor of 4 active clinical trials listed on ClinicalTrials.gov^[2], including 4 Phase 1^[1].

No Form 4 insider filings for FATE were recorded at the SEC in the past 30 days^[3].

Sources

ClinicalTrials.gov (2026-04-11) ↗
ClinicalTrials.gov (2026-04-11) ↗
SEC EDGAR · 0001434316 (2026-04-11) ↗

🏛

Upcoming Catalysts

FT576 — multiple myeloma

2026-11-05

in 154d

🔬

Clinical Trials

NCT04629729Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia

Source ↗

clinicaltrials_gov · Retrieved 2026-04-11

NCT06241456Advanced Solid Tumor

Source ↗

clinicaltrials_gov · Retrieved 2026-04-11

NCT06308978Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE)

Source ↗

clinicaltrials_gov · Retrieved 2026-04-11

NCT07216105Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma

Source ↗

clinicaltrials_gov · Retrieved 2026-04-11

👤

Insider Activity

0 filings

Source ↗

sec_edgar · Retrieved 2026-04-11

Not financial advice. BiotechSigns profiles are AI-generated from verified public sources (ClinicalTrials.gov, SEC EDGAR) and are for informational purposes only. Always do your own due diligence before making investment decisions.

Score Breakdown

Score Trend

2026-04-132026-06-02

Signal Summary

PDUFA Dates1

Insider Filings1

Clinical Trials1

Sector Peers (Cell Therapy)

ATRAAtara Biotherapeutics

VORVor Biopharma

IOVAIovance Biotherapeutics

ALLOAllogene Therapeutics